Virtual screening based on pharmacophoric features of known calpain inhibitors to identify potent inhibitors of calpain
- 346 Downloads
Calpain, a member of the group of cysteine protease enzymes, has been recognized as a promising drug target for several diseases, including cataract. In the present study, an attempt was made to identify potential inhibitors of calpain by employing a pharmacophore-based virtual screening and docking approach. A knowledge-based 3D pharmacophore model was generated, based on the features of established calpain inhibitors SJA6017, MDL28170, E64D, SNJ 1715, calpastatin and CHEMBL 1921830, using the PHASE module of Schrödinger Suite. The best pharmacophore model (AAADH) derived consisted of five features, namely three hydrogen bond acceptors, one hydrogen bond donor and one hydrophobic region. This common pharmacophore hypothesis was then used to perform virtual screening against a binding database, with due consideration to the Lipinski ‘rule of five’ and absorption, distribution, metabolism, excretion properties were calculated using the Qikprop module, so as to obtain a pool of lead molecules. The short-listed lead molecules were then subjected to docking analysis with that of the mutated calpain 1 (1KXR) to reduce the false positive and false negative results against the target receptor. Interaction data and its corresponding interaction energy, along with binding energy calculated for the hit ligand (650709) and mutated receptor (1KXR) complex, suggest that compound 650709 has a more effective inhibitory potential than that of the other established calpain inhibitors.
KeywordsCalpain inhibitor Cataract Pharmacophore model Virtual screening Molecular docking
Financial assistance provided by Council of Scientific & Industrial Research (CSIR), New Delhi in the form of Senior Research Fellowship to the first author is gratefully acknowledged (Ref. No. 09/475 (0185)/2012-EMR-I). Financial assistance provided by University Grants Commission-Basic Scientific Research (UGC-BSR) in the form of one time grant to the corresponding author is gratefully acknowledged. The authors Sanjeev Kumar Singh and Chandrabose Selvaraj also gratefully acknowledge CSIR for the funding grant (Ref. No. 37(1491)/11/EMR-II).
Conflict of interest
The authors declare that there are no conflicts of interest.
- Agarwal R, Iezhitsa I, Awaludin NA, Ahmad Fisol NF, Bakar NS, Agarwal P, Abdul Rahman TH, Spasov A, Ozerov A, Mohamed Ahmed Salama MS, Mohd Ismail N (2013) Effects of magnesium taurate on the onset and progression of galactose-induced experimental cataract: in vivo and in vitro evaluation. Exp Eye Res 110:35–43CrossRefPubMedGoogle Scholar
- Berman HM, Battistuz T, Bhat TN, Bluhm WF, Bourne PE, Burkhardt K, Feng Z, Gilliland GL, Iype L, Jain S, Fagan P, Marvin J, Padilla D, Ravichandran V, Schneider B, Thanki N, Weissig H, Westbrook JD, Zardecki C (2002) The protein data bank. Acta Crystallogr D Biol Crystallogr 58:899–907CrossRefPubMedGoogle Scholar
- Epik PPW (2011) Epik PPW, version 2.3. Schrödinger LLC, New YorkGoogle Scholar
- Glide (2011) Glide, version 5.7. Schrödinger, LLC, New YorkGoogle Scholar
- Impact (2011) Impact, version 5.8. Schrödinger LLC, New YorkGoogle Scholar
- LigPrep (2011) LigPrep, version 2.4. Schrödinger LLC, New YorkGoogle Scholar
- Maestro (2011) Maestro, version 9.2. Schrödinger LLC, New YorkGoogle Scholar
- Phase (2011) Phase, version 3.0. Schrödinger LLC, New YorkGoogle Scholar
- Prime (2011) Prime, version 3.0. Schrödinger LLC, New YorkGoogle Scholar
- Qikprop (2011) Qikprop, version 3.2. Schrödinger LLC, New YorkGoogle Scholar
- Sitemap (2011) Sitemap, version 2.5. Schrödinger LLC, New YorkGoogle Scholar
- Todd B, Moore D, Deivanayagam CC, Lin GD, Chattopadhyay D, Maki M, Wang KK, Narayana SV (2003) A structural model for the inhibition of calpain by calpastatin: crystal structures of the native domain VI of calpain and its complexes with calpastatin peptide and a small molecule inhibitor. J Mol Biol 328:131–146CrossRefPubMedGoogle Scholar